DRDanika Rodrigues

Danika Rodrigues

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danika Rodrigues has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ionic liquid–mediated cellular loading for whole tumor cell vaccines

    by Danika Rodrigues, Malini Mukherji, Kyung Soo Park, Maithili Joshi, Litsa Kapsalis, Suyog Shaha, Michael Griffith Bibbey, Metecan Erdi, Samir Mitragotri

    Conventional whole tumor cell cancer vaccines have demonstrated limited clinical success due to insufficient immunogenicity and challenges in adjuvant codelivery, despite their rich antigen repertoire and high patient-specific activity. Here, we introduce a simple, single-step approach to load immunostimulatory CpG oligodeoxynucleotides into tumor cells undergoing immunogenic cell death using an ionic liquid–containing cocktail. Results indicate that these adjuvant-loaded tumor cells (referred to as IL-Vax) enhance the uptake of cell-based vaccines by dendritic cells and their subsequent activation, leading to potent antitumor immunity. IL-Vax offered strong protection against tumor growth in a prophylactic B16F10 melanoma mouse model. Furthermore, IL-Vax synergized with PD-1 blockade to slow tumor growth and extend survival in a therapeutic model. The modularity of IL-Vax enables the loading of different cargos or cargo combinations, which may be conducive for additional tailoring of such vaccines and potentially other cell loading applications.

  • Open Access

    Multiscale red blood cell hitchhiking for targeted deep tissue gene delivery in lungs

    by Kyung Soo Park, Vineeth Chandran Suja, Jayoung Kim, Danika Rodrigues, Malini Mukherji, Maithili Joshi, Yongsheng Gao, Michael Griffith Bibbey, Jeong-Won Choi, Rick Liao, et al.

    The clinical impact of gene therapies is constrained by poor delivery to target tissues beyond the liver after intravenous administration. Current molecular targeting strategies, such as capsid engineering or gene-carrier surface modification, have achieved only limited success due to their inability to overcome the hierarchical barriers from injection to deep tissue transduction. Here, we introduce a Multiscale Approach using RBC-mediated hitchhiking and Vascular Endothelium Leakage (MARVEL), which integrates red blood cell hitchhiking with VEGF-induced vascular permeabilization to enhance accumulation and penetration of cargoes. Using adeno-associated viruses (AAVs) as a model, MARVEL markedly increases AAV localization in the lungs, improves endothelial transcytosis, and enables gene expression in deeper tissue layers while maintaining a favorable safety profile. We further demonstrate that MARVEL can be adopted into an in situ hitchhiking approach, bypassing the need for ex vivo formulation. MARVEL provides a scalable strategy to address long-standing delivery challenges in gene therapy.


  • Open Access

    A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease

    by Jayoung Kim, Yongsheng Gao, Zongmin Zhao, Danika Rodrigues, Eden E. L. Tanner, Kelly Ibsen, Pradip K. Sasmal, Rajasekhar Jaladi, Shanavas Alikunju, Samir Mitragotri

    Significance: Parkinson’s disease (PD) is a progressive disorder of the central nervous system that affects motor control. While subcutaneous injection of apomorphine (Apokyn) is clinically used to alleviate intermittent episodes of dyskinesia, the treatment requires multiple injections of the drug per day, significantly deterring patient compliance. We introduce a deep eutectic-based ternary solvent system that self-emulsifies in situ following subcutaneous injection and entraps apomorphine, allowing a 48-h duration of detectable drug concentration in the plasma of pigs, which is a remarkable improvement over the clinical comparator. The results from the animal studies support the self-emulsifying system as a potent, long-lasting therapeutic for PD patients and potentially for other therapeutics that have a similar delivery challenge.